ADC Therapeutics SA Tax Withholding Paid on Stock Awards
ADC Therapeutics SA (ADCT) reported Tax Withholding Paid on Stock Awards of $985.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-13
- ADC Therapeutics SA payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $217.00K, a 13.20% decline year-over-year.
- ADC Therapeutics SA payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $768.00K.
- ADC Therapeutics SA payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $1.26M, a 8.68% increase year-over-year.
- ADC Therapeutics SA payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $0.00.
- ADC Therapeutics SA payment, tax withholding, share-based payment arrangement for fiscal 2025 was $1.51M, a 30.18% increase from fiscal 2024.
- ADC Therapeutics SA payment, tax withholding, share-based payment arrangement for fiscal 2024 was $1.16M.
- ADC Therapeutics SA payment, tax withholding, share-based payment arrangement for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ADC Therapeutics SA payment, tax withholding, share-based payment arrangement for fiscal 2022 was $1.31M.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $217.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $985.00K 10-Q · filed 2026-08-13 | $2.25M derived: sum of 3 quarters · filed 2026-08-13 | $2.25M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $768.00K 10-Q · filed 2026-05-04 | $2.03M derived: sum of 2 quarters · filed 2026-05-04 | $2.03M derived: sum of 3 quarters · filed 2026-05-04 | $2.28M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $1.26M derived: sum of 2 quarters · filed 2026-03-10 | $1.51M derived: sum of 3 quarters · filed 2026-08-13 | $1.51M 10-K · filed 2026-03-10 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $250.00K derived: sum of 2 quarters · filed 2026-08-13 | $250.00K 10-Q · filed 2025-11-10 | $1.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $250.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $250.00K 10-Q · filed 2026-08-13 | $1.41M derived: sum of 3 quarters · filed 2026-08-13 | $1.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-04 | $1.16M derived: sum of 2 quarters · filed 2026-05-04 | $1.16M derived: sum of 3 quarters · filed 2026-05-04 | |
| 2024-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $1.16M derived: sum of 2 quarters · filed 2026-03-10 | $1.16M 10-K · filed 2026-03-10 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-27 | |||
| 2022-12-31 | $1.31M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |